Table 3.
Risk score model outcomes
| CHU Sourô Sanou | CePReF | CHUSO | CIRBA | Total | D:A:D cohort [5] | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||||
| Baseline score [median (IQR)] | −2 | (−5–4) | −2 | (−5–1) | 1 | (−2–5) | −1 | (−3–3) | −2 | (−5–3) | −2 | (−4–2) |
| Baseline score for those who developed CKD [median (IQR)] | 6 | (3–11) | 5 | (−1–10) | 8 | (5–11) | 7 | (1–11) | 6 | (1–11) | 10 | (5–13) |
| CKD incidence [per 1000 PYFU (95% CI)] | ||||||||||||
| Low (score < 0) | 2.24 | (1.66–3.03) | 2.50 | (1.93–3.23) | 1.57 | (0.59–4.17) | 2.75 | (1.93–3.91) | 2.42 | (2.05–2.86) | 0.56 | (0.38–0.75) |
| Medium (score 0–4) | 8.07 | (6.07–10.75) | 8.25 | (6.03–11.30) | 3.98 | (1.79–8.87) | 9.78 | (6.84–13.99) | 8.07 | (6.76–9.64) | 4.67 | (3.80–5.53) |
| High (score ≥ 5) | 28.09 | (23.85–33.10) | 35.75 | (30.10–42.45) | 19.48 | (13.85–27.41) | 37.14 | (30.40–45.33) | 30.91 | (28.03–34.08) | 36.05 | (32.86–39.23) |
| Incidence rate ratio (95% CI) | ||||||||||||
| Low (score < 0) | 0.28 | (0.18–0.42) | 0.30 | (0.20–0.45) | 0.39 | (0.11–1.39) | 0.28 | (0.17–0.46) | 0.30 | (0.23–0.38) | 0.12 | (0.08–0.18) |
| Medium (score 0–4) | 1 | 1 | 1 | 1 | 1 | |||||||
| High (score ≥ 5) | 3.48 | (2.50–4.84) | 4.33 | (3.03–6.20) | 4.89 | (2.05–11.67) | 3.80 | (2.52–5.72) | 3.83 | (3.13–4.69) | 7.73 | (6.29–9.49) |
| Kaplan-Meier [% progressed at 5 years (95% CI)] | ||||||||||||
| Low (score < 0) | 0.73 | (0.46–1.17) | 0.99 | (0.69–1.41) | 0.8 | (0.3–2.14) | 0.81 | (0.47–1.40) | 0.86 | (0.67–1.10) | 0.19 | (0.10–0.27) |
| Medium (score 0–4) | 3.90 | (2.73–5.56) | 4.10 | (2.83–5.92) | 1.76 | (0.71–4.34) | 3.51 | (2.18–5.62) | 3.63 | (2.91–4.51) | 1.62 | (1.19–2.05) |
| High (score ≥ 5) | 14.16 | (11.86–16.85) | 16.79 | (13.97–20.10) | 9.21 | (6.45–13.08) | 17.34 | (13.95–21.44) | 14.74 | (13.27–16.35) | 15.33 | (13.82–16.84) |
| aIRR per unit increase score (95% CI) | 1.23 | (1.20–1.26) | 1.24 | (1.22–1.27) | 1.21 | (1.15–1.28) | 1.22 | (1.19–1.25) | 1.23 | (1.21–1.24) | 1.32 | (1.31–1.34) |
CHU Sourô Sanou, University Teaching Hospital Sourô Sanou in Bobo Dioulasso, Burkina Faso; CePReF, the Centre de Prise en Charge, de Recherche et de Formation; CIRBA, Centre Intégré de Recherches Biocliniques d’Abidjan, Abidjan, Côte d’Ivoire; CHUSO, University Teaching Hospital Sylvanus Olympio, Lomé, Togo; aIRR, adjusted incidence rate ratio; CKD, chronic kidney disease; IQR, interquartile range; PYFU, person-years of follow-up; CI, confidence interval.